PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$13.77
0.11 (0.84%)
▲
5d:
+3.77%
30d:
+12.13%
90d:
-18.62%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
26d
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PHAR shows positive signals but monitor for confirmation. Market pricing in 1.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: PHAR shows positive signals but monitor for confirmation. Market pricing in 1.2% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $13.77, which is considered extended relative to its 30-day fair value range of $12.51 to $13.45. The stock's valuation (Forward PE: 210.2) is in line with its historical norms (217.8). Remarkably, the market is currently pricing in an annual earnings decline of 1.2% over the next few years. This pessimistic expectation contrasts with the company's recent 104.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHAR is in a strong downtrend. The price is approaching resistance at $13.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHAR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.35 (+149.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAR is in a strong downtrend. The price is approaching resistance at $13.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHAR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.35 (+149.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.51 -
$13.45
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 149.5% below Wall St target ($34.35)
Trading Range Analysis
30-Day Trading Range
$12.51 -
$13.45
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$12.71
Resistance Level
$13.97
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
210.23
Wall Street Target
$34.35
(+149.5%)
Revenue Growth (YoY)
-8.4%
Earnings Growth (YoY)
104.2%
Profit Margin
3.3%
Valuation Discount vs History
-1.2% cheaper
PE vs Historical
210.2 vs 217.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.2%
(market-implied from PE analysis)
1-Year Target
$13.60
(-1%)
2-Year Target
$13.44
(-2%)
3-Year Target
$13.28
(-4%)
3-Yr Target (if PE normalizes)
(PE: 210→218)
$13.76
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 210.2, Growth: -71.6%)
$10.04
(+-27%)
Base:
(SPY PE: 21.8, Growth: -71.6%)
$1.04
(-92%)
Bear:
(PE: 18.5, Growth: -71.6%)
$0.88
(-94%)
📈
Valuation based on Current Earnings
Forward PE: 24.21 | Forward EPS (Implied): $0.57
Bull Case
$16.63
(+21%)
Analyst growth 15.0%, PE expands to 25.4
Base Case
$13.77
(0%)
Market implied 0.0%, PE stable at 24.2
Bear Case
$10.53
(-24%)
Severe decline -15.0%, PE contracts to 21.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 210.2 to 217.8
Stabilization Target:
$14.27
(+3.6%)
PE Expansion Potential:
+3.6%
Share & Embed Analysis
Last updated: July 02, 2026 10:53 PM ET
Data refreshes hourly during market hours. Next update: 11:53 PM
Data refreshes hourly during market hours. Next update: 11:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
